SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Exterior of the FDA headquarters in Mary
Drug Development
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Regeneron’s bispecific antibody odronextamab was hit with Complete Response Letters from the FDA noting issues with the enrollment status of its confirmatory trials.
March 25, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Illustration of gloved hands using tools
Biotech Bay
Eledon’s Antibody Aids First Gene-Edited, Pig-to-Human Kidney Transplant
Tegoprubart, Eledon Pharmaceuticals’ experimental anti-CD40L antibody, was part of the immunosuppressive treatment regimen used following the first-ever transplant of a kidney from a genetically modified pig to a human.
March 22, 2024
 · 
4 min read
 · 
Tyler Patchen
Biotech Beach
Capstan Secures $175M Oversubscribed Series B with Backing from J&J, Bayer and BMS
Capstan Therapeutics is looking to move its CAR-T cell candidate forward after securing financing from pharma venture arms and VC firms.
March 21, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3d illustration of antibodies attacking
Business
Mirador Launches with $400M in Funding, Targets Precision Medicines
Mirador Therapeutics emerged from stealth Thursday with financing from ARCH Venture Partners and Sanofi, among others, to provide precision medicines for inflammatory and fibrotic diseases.
March 21, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Boy in a wheelchair looking out the window
Drug Development
Italfarmaco Touts Positive Results in Phase III DMD Trial Ahead of PDUFA
In advance of a March 21 PDUFA date, Italfarmaco on Tuesday reported that its drug candidate givinostat met the primary endpoint for treating Duchenne muscular dystrophy.
March 20, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Lonza Facility in TX/iStock, JHVEPhoto
Deals
Lonza to Buy Roche Biologics Manufacturing Site in California for $1.2B
The contract manufacturer plans to expand its U.S. footprint with a former Roche facility in Vacaville, California, which Lonza contends is one of the largest biologics manufacturing facilities in the world by volume.
March 20, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: A collage of Trump, the U.S. Capitol and
Policy
What Another Trump Presidency Could Mean for Big Pharma
President Joe Biden has made drug pricing a cornerstone of his campaign, but former President Donald Trump also plans to target drugmakers if he reenters the White House.
March 20, 2024
 · 
5 min read
 · 
Tyler Patchen
Pictured: Anxious man with his head in his hands/i
Drug Development
Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward
Engrail Therapeutics’ latest financing round will give it enough funds to advance its candidates for neuropsychiatric and neurodevelopmental disorders through clinical development.
March 19, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: AstraZeneca's building in Shanghai, China
Drug Delivery
AstraZeneca Caps US Inhaler Out-of-Pocket Costs on Heels of Boehringer
With Boehringer Ingelheim’s announcement earlier this month that it was capping U.S. inhaler costs at $35 per month, AstraZeneca on Monday followed suit.
March 18, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pfizer's signage at its world headquarters in New York
Pharm Country
Pfizer to Lower Its Stake in GSK Consumer Health Spinoff Haleon
Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.
March 18, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: FDA signage at its office in Washington, DC
Policy
FDA Adcomm Backs J&J’s Carvykti, BMS’s Abecma Early in Multiple Myeloma
By votes of 11-0 and 8-3, respectively, an FDA advisory committee Friday deemed the risks of early death for both Johnson & Johnson’s Carvykti and Bristol Myers Squibb’s Abecma acceptable.
March 15, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Gene therapy illustration showing an inj
Drug Development
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer
Asgard Therapeutics, a Swedish gene therapy biotech, has closed a $32 million Series A round with help from prominent pharma players as it prepares for a 2026 IND.
March 15, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bayer's global pharmaceuticals headquarters in Germany
Business
Bayer, AI-Focused Aignostics Partner to Find New Oncology Targets
Bayer will co-create a novel target identification platform that leverages Aignostics’ artificial intelligence technology and proprietary multimodal patient cohorts.
March 15, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D rendering of antibody-drug conjugate/
Business
Biotheus, Hansoh Expand Partnership in $694M ADC Deal
The Chinese biotechs are broadening their collaboration. Hansoh Pharma is licensing Biotheus’ anti-EGFR/cMet bispecific antibody to develop antibody-drug conjugates.
March 15, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Astellas Pharma US headquarters in Illinois
Business
Astellas Backs Out of Potential $340M Licensing Deal with Cartesian
After forging a partnership last year, Astellas is ending the pact with Cartesian Therapeutics and stopping the development of a Pompe disease candidate.
March 15, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More